000 02170cam  2200385zi 4500
0019.909078
003CaOODSP
00520221107181823
006m     o  d f      
007cr |||||||||||
008220314e20220407onc     ob   f000 0 eng d
020 |a9780660425481
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH139-39/2022E-PDF
24500|aGood manufacturing practices inspection policy for drug establishments : |bPOL-0011.
264 1|a[Ottawa] : |bHealth Canada = Santé Canada, |cApril 7, 2022.
264 4|c©2022
300 |a1 online resource (22 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Politique d'inspection des bonnes pratiques de fabrication pour les établissements de drogues : POL-0011.
500 |a"Pub.: 210725."
500 |aIssued also in HTML format.
504 |aIncludes bibliographical references (pages 20-22).
520 |a"Establishments need a drug establishment license (DEL) to be authorized to conduct the following licensable activities: fabricate, package/label, test, import, distribute, or wholesale of drugs. Health Canada inspects these sites to verify requirements for good manufacturing practices (GMP) are met before DEL issuance. This helps ensure that safety and quality standards are met by those selling drugs to Canadians"--Purpose, page 4.
650 0|aPharmaceutical industry|xLicenses|zCanada.
650 0|aPharmaceutical industry|zCanada|xQuality control.
650 0|aDrugs|xStandards|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tPolitique d'inspection des bonnes pratiques de fabrication pour les établissements de drogues : |w(CaOODSP)9.909079
85640|qPDF|s930 KB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H139-39-2022-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/policies-standards/inspection-policy-canadian-drug-establishments.html